Foamix has received a patent for its Oil-Gel compositions, which primarily comprise hydrophobic solvents, suitable for the delivery of a broad range of pharmaceutical agents targeting various diseases and disorders of the skin and the eye. Foamix now has 20 issued US patents.
The company’s lead product, Minocycline Foam, is the first-ever topical minocycline which can be used for the treatment of acne, rosacea and skin infections. Foamix’s current Phase II study has shown its Minocycline Foam to be a safe and effective topical treatment and an alternative to oral antibiotics, with superior efficacy and no significant side effects.
Minocycline, a well-known broad-spectrum antibiotic, is taken mainly for the treatment of Acne, available only in oral dosage form. Foamix believes that a topical Minocycline foam could capture a significant portion of the oral anti-acne and anti-rosacea drug market, currently worth over US $1 billion per annum, as
To date, Foamix has 55 granted patents worldwide, including 20 issued patents in the United States. Additionally, the company has more than 135 pending patent applications worldwide, of which over 70 applications are filed in the U.S.